These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29746728)

  • 1. An Open-Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics.
    Li Y; Wang X; Liu L; Zhang C; Gomez D; Reyes J; Palmisano M; Zhou S
    Clin Pharmacol Drug Dev; 2019 Apr; 8(3):346-354. PubMed ID: 29746728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects.
    Li Y; Liu L; Wang X; Zhang C; Reyes J; Hoffmann M; Palmisano M; Zhou S
    J Clin Pharmacol; 2018 Oct; 58(10):1295-1304. PubMed ID: 29762875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
    Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
    Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
    Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
    Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
    Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
    Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.
    Peveling-Oberhag J; Zeuzem S; Yong WP; Kunz T; Paquet T; Bouillaud E; Urva S; Anak O; Sellami D; Kobalava Z
    Clin Ther; 2013 Mar; 35(3):215-25. PubMed ID: 23453404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
    Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
    Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
    Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol.
    Bramer SL; Forbes WP
    Clin Pharmacokinet; 1999; 37 Suppl 2():25-32. PubMed ID: 10702884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asenapine pharmacokinetics in hepatic and renal impairment.
    Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
    Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pomalidomide for the management of refractory multiple myeloma.
    Summers BB; Cole SW; Olin JL
    Am J Health Syst Pharm; 2014 Sep; 71(17):1443-8. PubMed ID: 25147167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
    Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
    Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects.
    Flanagan S; Ong V; Marbury T; Jandourek A; Gandhi RG; Sandison T
    Pharmacotherapy; 2024 Jun; 44(6):435-443. PubMed ID: 38840536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
    Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
    Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib.
    Magee MH; Shearn S; Shaddinger B; Fang Z; Glaser R
    Br J Clin Pharmacol; 2014 Nov; 78(5):1014-21. PubMed ID: 24938621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment
.
    Kulmatycki KM; Langenickel T; Ng WH; Pal P; Zhou W; Lin TH; Rajman I; Chandra P; Sunkara G
    Int J Clin Pharmacol Ther; 2017 Sep; 55(9):728-739. PubMed ID: 28737127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
    Zhao Q; Iyer GR; Verhaeghe T; Truyen L
    J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment.
    Grasela DM; Christofalo B; Kollia GD; Duncan G; Noveck R; Manning JA; LaCreta FP
    Pharmacotherapy; 2000 Jun; 20(6 Pt 2):87S-94S. PubMed ID: 10850525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
    Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
    Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
    Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.